EC
KLRS

EcoR1 Capital’s Kalaris Therapeutics KLRS Stock Holding History

EcoR1 Capital’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-201,718
Closed -$1.62M – 52
2025
Q1 		$1.62M Buy
201,718
+183,949
+1,035% +$1.8M 0.1% 38
2024
Q4 		$3.95M Sell
17,769
-473,300
-96% -$7.16M 0.16% 46
2024
Q3 		$9.13M Hold
491,069
– – 0.31% 43
2024
Q2 		$8.17M Hold
491,069
– – 0.25% 43
2024
Q1 		$8.53M Buy
+491,069
New +$8.01M 0.22% 45
2021
Q3 		– Sell
-19,435
Closed -$8.82M – 78
2021
Q2 		$8.82M Hold
19,435
– – 0.33% 37
2021
Q1 		$10.5M Hold
19,435
– – 0.47% 30
2020
Q4 		$17.2M Hold
19,435
– – 0.96% 23
2020
Q3 		$12.3M Buy
+19,435
New +$13.3M 0.89% 22

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Squarepoint
Squarepoint New York $46.5B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return